辅助生殖概念持续走强，汉商集团、福元医药、利德曼涨停，共同药业、达嘉维康、思创医惠、博拓生 物、贝瑞基因、麦迪科技等跟涨。 ...

近日，北京福元医药股份有限公司（以下简称"公司"）收到了国家药品监督管理局（以下简称"国家药 监局"）颁发的兰索拉唑肠溶胶囊（规格：15mg；30mg）（以下简称"该药品"）《药品注册证书》（证 书编号：2025S02336、2025S02337），批准该药品生产。现将相关情况公告如下： 一、药品注册证书主要内容 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ■ 二、药品相关信息 由Takeda研制的兰索拉唑肠溶胶囊，最早于1990年12月31日获法国批准上市，1996年12月6日，经国家 药品监督管理局批准，兰索拉唑肠溶胶囊在国内上市，用于胃溃疡、十二指肠溃疡、反流性食管炎、 卓-艾综合征（Zollinger-Ellison症候群）、吻合口溃疡。 公司于2024年4月25日获得申报受理通知书，并于近日获得国家药监局批准。根据国家相关政策规定， 本次获得《药品注册证书》，为视同通过一致性评价。 截至本公告日，公司针对该药品累计研发投入为人民币583.23万元(未经审计)。 2025年8月1日 三、同类药品的市场状况 米内网数 ...

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Group 1 - The core point of the article is that Fuyuan Pharmaceutical has received the drug registration certificate for Lansoprazole enteric-coated capsules from the National Medical Products Administration, allowing the company to commence production of the drug [2] Group 2 - The approved specifications for the drug are 15mg and 30mg [2] - This approval represents a significant milestone for the company in expanding its product offerings in the pharmaceutical market [2] - The announcement was made on the evening of July 31 [2]

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

2024年1至12月份，福元医药的营业收入构成为：药品制剂占比93.12%，医疗器械占比6.46%，其他业 务占比0.36%，其他占比0.06%。 福元医药（SH 601089，收盘价：24.13元）7月31日晚间发布公告称，近日，北京福元医药股份有限公 司收到了国家药品监督管理局颁发的兰索拉唑肠溶胶囊《药品注册证书》，批准该药品生产。 （文章来源：每日经济新闻） ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Lansoprazole enteric-coated capsules, indicating approval for production [1] Company Summary - The approved Lansoprazole enteric-coated capsules are available in two specifications: 15mg and 30mg [1] - Lansoprazole was developed by Takeda and was first approved for sale in France on December 31, 1990 [1] - The drug was approved for domestic sale in China on December 6, 1996, and is indicated for conditions such as gastric ulcers, duodenal ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and anastomotic ulcers [1] Industry Summary - The approval of Lansoprazole enteric-coated capsules reflects ongoing regulatory support for pharmaceutical products aimed at treating gastrointestinal disorders [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-054 北京福元医药股份有限公司 关于兰索拉唑肠溶胶囊获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 公司于 2024 年 4 月 25 日获得申报受理通知书，并于近日获得国 家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》， 为视同通过一致性评价。 截至本公告日，公司针对该药品累计研发投入为人民币 583.23 万元(未经审计)。 三、同类药品的市场状况 米内网数据显示，2024 年中国三大终端六大市场兰索拉唑（口服 剂型：胶囊剂、片剂）的销售额约为 100,571 万元，其中城市公立医 院和县级公立医院销售额为 73,807 万元，城市社区中心和乡镇卫生院 销售额为 16,080 万元，城市实体药店和网上药店销售额为 10,684 万 元。 四、对公司的影响及风险提示 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的兰索拉唑肠 溶胶囊（规格：15mg；30mg ...

Core Viewpoint - The company has received the drug registration certificate for Lansoprazole enteric-coated capsules, which will enhance its product line and market competitiveness [1] Group 1 - The National Medical Products Administration has issued a drug registration certificate for Lansoprazole enteric-coated capsules in 15mg and 30mg specifications [1] - The drug is considered to have passed the consistency evaluation, indicating its quality and efficacy [1] - The total R&D investment for this drug by the company amounts to RMB 5.8323 million [1]

Core Viewpoint - The A-share assisted reproductive sector is experiencing significant growth, with multiple companies reaching new highs and notable stock price increases [1] Company Performance - Fuyuan Pharmaceutical reached an all-time high during trading [1] - Gongtong Pharmaceutical, Hanshang Group, and Lide Man all hit the daily limit up [1] - Anke Bio increased by over 15% [1] - Guangshengtang rose by over 10% [1] - Other companies such as Xinguang Pharmaceutical, Dajia Weikang, BeiYinMei, Xinghao Pharmaceutical, and Beirui Gene also saw price increases [1]